Summary: The industry is at a unique crossroads: pharmaceutical and digital therapeutic (DTx) companies have begun to act on their ambition to advance digital therapeutics—but the path to successful alliances and, importantly, scale remains uncertain. As a follow up to our recent research on building pharma-DTx alliances, we sat down with two leaders to get their perspective on: -The dos and don'ts of pharma-DTx partnerships -Evidence standards for digital therapeutics -Channel pathways and business models for DTx companies -Assessing the value of working with pharma as a DTx company Hear from ZS' Paul Darling, Novo Nordisk's Amy West, Pear Therapeutics' Corey McCann, and Rock Health's Megan Zweig in our latest podcast episode.
